Shen Zhaohua, Zhu Changxin, Quan Yongsheng, Yuan Wei, Wu Shuai, Yang Zhenyu, Luo Weiwei, Tan Bei, Wang Xiaoyan
Department of Gastroenterology, Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Hunan Key Laboratory of Non-Resolving Inflammation and Cancer, Changsha, Hunan, China.
J Gastroenterol Hepatol. 2017 Nov;32(11):1804-1812. doi: 10.1111/jgh.13861.
The pathogenesis of Crohn's disease (CD) is complex, and it is thought to be associated with the environment, immune, hereditary, microbe, and other factors. If the balance between the host and the intestinal microbes in CD patients was broken, immune-inflammatory response of susceptible individuals might be triggered. Probiotics could improve the intestinal microbial flora balance and treat human effectively. There are several new mechanisms that might explain the role of probiotics. Fecal microbiota transplantation (FMT) is becoming more and more attractive in treating a large amount of digestive system diseases that are related to the dysbiosis of intestinal microbiota. FMT has been widely used in recurrent Clostridium difficile infection. More and more attention has been paid on the clinical application of FMT in CD, while the exact mechanism is still a mystery. So in this review, we explore the mechanism, clinical application, and adverse reactions of intestinal microbiota in CD so that we can use the tool to cure more diseases. Enteric microbiota leads to new therapeutic strategies for CD.
克罗恩病（CD）的发病机制复杂，被认为与环境、免疫、遗传、微生物等因素有关。如果CD患者体内宿主与肠道微生物之间的平衡被打破，可能会触发易感个体的免疫炎症反应。益生菌可以改善肠道微生物菌群平衡并有效治疗人类疾病。有几种新机制可能解释益生菌的作用。粪便微生物群移植（FMT）在治疗大量与肠道微生物群失调相关的消化系统疾病方面越来越具有吸引力。FMT已广泛应用于复发性艰难梭菌感染。FMT在CD中的临床应用越来越受到关注，但其确切机制仍是个谜。因此，在本综述中，我们探讨了肠道微生物群在CD中的机制、临床应用及不良反应，以便我们能利用这一工具治愈更多疾病。肠道微生物群为CD带来了新的治疗策略。
